- BioLineRx (NASDAQ:BLRX) in-licenses a novel anti-inflammatory treatment for dry eye syndrome (DES) from Hebrew University of Jerusalem. The product candidate, BL-1230, is the third project in the company's strategic collaboration with Novartis Pharma AG (NVS).
- BL-1230 is a selective cannabinoid receptor type 2 (CB2R) agonist. BioLineRx plans to explore its use in treating systemic inflammatory conditions as well.
- The financial terms of the license are not disclosed.
BioLineRx nabs rights to DES candidate from Hebrew University
Recommended For You
More Trending News
About BLRX Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
BLRX | - | - |
BioLineRx Ltd. |